• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters
Displaying 114-128 of 153 results

1038 Exhibit: Ex 1038 Office Action from US Patent Office re US Patent Application...

Document IPR2022-00215, No. 1038 Exhibit - Ex 1038 Office Action from US Patent Office re US Patent Application No 13768,906 May 24, 2013 (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1019 Exhibit: Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hik...

Document IPR2022-00215, No. 1019-4 Exhibit - Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hikma Pharms USA Inc, No 16 2525 D Nev Part 4 (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1031 Exhibit: Ex 1031 Amarin Supplemental Response to US Patent Office re US P...

Document IPR2022-00215, No. 1031 Exhibit - Ex 1031 Amarin Supplemental Response to US Patent Office re US Patent Application No 13614,111 Jan 11, 2013 (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1011 Exhibit: Ex 1011 Vital and Health Statistics, Serum Lipids of Adults 20 74 Yea...

Document IPR2022-00215, No. 1011 Exhibit - Ex 1011 Vital and Health Statistics, Serum Lipids of Adults 20 74 Years United States, 1976 80, 11242, Natl Health Survey, US Dept Health Human Servs Mar...

cite Cite Document
Analyze

1034 Exhibit: Ex 1034 World Health Organization Memorandum, Classification of H...

Document IPR2022-00215, No. 1034 Exhibit - Ex 1034 World Health Organization Memorandum, Classification of Hyperlipoproteinemias, 43891, 501 508 1972 (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1018 Exhibit: Ex 1018 Day 7 Jan 28, 2020 Trial Transcript from Amarin Pharma, Inc...

Document IPR2022-00215, No. 1018 Exhibit - Ex 1018 Day 7 Jan 28, 2020 Trial Transcript from Amarin Pharma, Inc v Hikma Pharms USA Inc, No 16 2525 D Nev Testimony of Dr Toth (P.T.A.B. Nov. 30, 20...

cite Cite Document
Analyze

1020 Exhibit: Ex 1020 Plaintiffs Infringement Contentions from Amarin Pharma, Inc...

Document IPR2022-00215, No. 1020 Exhibit - Ex 1020 Plaintiffs Infringement Contentions from Amarin Pharma, Inc et al vs Hikma Pharms USA Inc et al, CA No 20 1630 D Del (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1026 Exhibit: Ex 1026 Davidson et al, Efficacy and Tolerability of Adding Prescriptio...

Document IPR2022-00215, No. 1026 Exhibit - Ex 1026 Davidson et al, Efficacy and Tolerability of Adding Prescription Omega 3 Fatty Acids 4 gd to Simvastatin 40 mgd in Hypertriglyceridemic Patients (P.T...

cite Cite Document
Analyze

1015 Exhibit: Ex 1015 Nozaki et al, Effects of Purified Eicosapentaenoic Acid Ethyl...

Document IPR2022-00215, No. 1015 Exhibit - Ex 1015 Nozaki et al, Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia, 62 Intl J Vitamin Nutr R...

cite Cite Document
Analyze

1008 Exhibit: Ex 1008 Third Report of the National Cholesterol Education Program ...

Document IPR2022-00215, No. 1008 Exhibit - Ex 1008 Third Report of the National Cholesterol Education Program N CEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol i...

cite Cite Document
Analyze

1030 Exhibit: Ex 1030 US Patent Office Interview Summary re US Patent Applicatio...

Document IPR2022-00215, No. 1030 Exhibit - Ex 1030 US Patent Office Interview Summary re US Patent Application No 13614,111 Dec 12, 2012 (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1029 Exhibit: Ex 1029 FDA Briefing Document, Endocrinologic and Metabolic Drugs...

Document IPR2022-00215, No. 1029 Exhibit - Ex 1029 FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting regarding ANCHOR trial Oct 16, 2013 (P.T.A.B. Nov. 30, ...

cite Cite Document
Analyze

1037 Exhibit: Ex 1037 Hikmas Motion to Dismiss from Amarin Pharma, Inc et al vs H...

Document IPR2022-00215, No. 1037 Exhibit - Ex 1037 Hikmas Motion to Dismiss from Amarin Pharma, Inc et al vs Hikma Pharms USA Inc et al, CA No 20 1630 D Del (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1033 Exhibit: Ex 1033 Vascepa Label 122019

Document IPR2022-00215, No. 1033 Exhibit - Ex 1033 Vascepa Label 122019 (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze

1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 12

Document IPR2022-00215, No. 1013-12 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 12 (P.T.A.B. Nov. 30, 2021)

cite Cite Document
Analyze
<< 1 2 3 4 5 ... 8 9 10 11 >>